10028366An innovative non-invasive retinal biomarker for drug discovery leading to improved diagnostics and better treatments for Multiple Sclerosis patientsClosedCollaborative R&DInnovate UKNovai Ltd (Novai) is a UK biotech SME with a core project team of Dr John Maddison (Project Lead/CTO), Dr Jonathan Young (Data Scientist) and Professor Francesca Cordeiro (Scientific Lead). Novai is aiming to develop its retinal biomarker, DARC, for earlier disease detection so it can be used to identify and monitor progression in MS patients. This innovative biomarker will reduce R&D timelines and facilitate appropriate trial patient recruitment, leading to quicker and more accurate patient diagnostics and the introduction of better treatments sooner. It will replace current cumbersome and invasive biomarkers, improving the quality of life of MS patients and reducing morbidity/mortality. It has the potential to become a valuable companion of the UK government's Progressive Neurological Conditions Toolkit, which covers MS.